BRK-B vs MC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Moelis & Company demonstrates strong operational health, evidenced by a Piotroski F-Score of 7/9 and an exceptional ROE of 44.77%. However, the stock is trading at a severe premium, with the current price of $67.05 significantly exceeding both the Graham Number ($22.63) and the Intrinsic Value ($20.58). While the company has a stellar recent track record of earnings beats (4/4), the high dividend payout ratio of 88.44% and bearish technical trends suggest a lack of immediate catalyst for further growth. Fundamentally, the company is a high-performer trading at a high valuation.
Compare Another Pair
Related Comparisons
BRK-B vs MC: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Moelis & Company (MC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.